View Exam | PowerPak

1. The most common cause of death in patients with venous thromboembolism is

A. Deep vein thrombosis B. Pulmonary hypertension C. Postphlebitic syndrome D. Pulmonary embolism

2. Which of the following is the most common cause of hospital-associated deaths in the United States?

A. Nosocomial pneumonia B. Adverse drug events C. Venous thromboembolism D. Catheter-associated blood stream infections

3. What proportion of patients with a venous thromboembolism event have at least one identifiable risk factor?

A. One-tenth B. One-third C. Two-thirds D. Three-quarters

4. Which of the following is NOT a risk factor associated with venous thromboembolism event in patients hospitalized with an acute medical illness?

A. Ambulation B. Infection C. A D-dimer concentration 2 times the upper limit of normal D. Acute heart failure

5. A 56-year-old man (body mass index, 28 kg/m²) is admitted to the coronary intensive care unit at the hospital with signs and symptoms of acute heart failure (leg edema and shortness of breath). He has a history of heart failure with reduced ejection fraction for 2 years, idiopathic cardiomyopathy, deep vein thrombosis 5 years ago, and 2 prior hospitalizations for heart failure. His anticipated length of hospital stay is 5 days. What is this patient's IMPROVE risk score and interpretation of the risk of venous thromboembolism in the next 90 days?

A. 2 points; low risk B. 3 points; high risk C. 4 points; high risk D. 5 points; high risk

6. Which of the following agents is approved by the Food and Drug Administration for extended outpatient venous thromboembolism prophylaxis in adult patients with acute medical illness?

A. Enoxaparin B. Betrixaban C. Rivaroxaban D. Unfractionated heparin

7. Observational and clinical trials indicate that the highest frequency of VTE events in acutely ill medical patients occurs during which of the following time periods?

A. The first day of admission B. During the hospital admission C. Between hospital discharge and 30 days D. Between 2 months and 6 months after hospital discharge

8. Which of the following is the correct interpretation of the clinical trial data evaluating short-term versus extended-duration venous thromboembolism prophylaxis in hospitalized patients?

A. Extended-duration rivaroxaban or apixaban reduced the frequency of venous thromboembolism but increased the frequency of major or major plus clinically relevant nonmajor bleeding compared with short-term enoxaparin. B. Extended-duration betrixaban or rivaroxaban reduced the frequency of venous thromboembolism but increased the frequency of major or major plus clinically relevant nonmajor bleeding compared with short-term enoxaparin. C. Extended-duration rivaroxaban had similar frequency of venous thromboembolism and similar frequency of major bleeding compared with short-term enoxaparin. D. Extended-duration betrixaban had reduced frequency of venous thromboembolism and similar frequency of major bleeding compared with short-term enoxaparin.

9. The dose of betrixaban approved by the Food and Drug Administration for a patient hospitalized with acute heart failure, creatinine clearance of 40 mL/min, and a history of heart failure with reduced ejection fraction who is receiving amiodarone for treatment of ventricular tachycardia is

A. 160 mg loading dose and 80 mg daily for the duration of hospitalization B. 80 mg loading dose and 40 mg daily for the duration of hospitalization C. 160 mg loading dose and 80 mg daily for 35 days D. 80 mg loading dose and 40 mg daily for 35 days

10. The 2012 practice guidelines of the American College of Chest Physicians recommend which of the following options for venous thromboembolism prophylaxis in acutely ill medical patients?

A. Enoxaparin for the duration of hospitalization B. Enoxaparin for 35 to 42 days C. Unfractionated heparin 7500 units three times daily for the duration of hospitalization D. Unfractionated heparin 7500 units three times daily for 35 to 42 days

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. The most common cause of death in patients with venous thromboembolism is

2. Which of the following is the most common cause of hospital-associated deaths in the United States?

3. What proportion of patients with a venous thromboembolism event have at least one identifiable risk factor?

4. Which of the following is NOT a risk factor associated with venous thromboembolism event in patients hospitalized with an acute medical illness?

6. Which of the following agents is approved by the Food and Drug Administration for extended outpatient venous thromboembolism prophylaxis in adult patients with acute medical illness?

7. Observational and clinical trials indicate that the highest frequency of VTE events in acutely ill medical patients occurs during which of the following time periods?

8. Which of the following is the correct interpretation of the clinical trial data evaluating short-term versus extended-duration venous thromboembolism prophylaxis in hospitalized patients?

9. The dose of betrixaban approved by the Food and Drug Administration for a patient hospitalized with acute heart failure, creatinine clearance of 40 mL/min, and a history of heart failure with reduced ejection fraction who is receiving amiodarone for treatment of ventricular tachycardia is

10. The 2012 practice guidelines of the American College of Chest Physicians recommend which of the following options for venous thromboembolism prophylaxis in acutely ill medical patients?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. The most common cause of death in patients with venous thromboembolism is

2. Which of the following is the most common cause of hospital-associated deaths in the United States?

3. What proportion of patients with a venous thromboembolism event have at least one identifiable risk factor?

4. Which of the following is NOT a risk factor associated with venous thromboembolism event in patients hospitalized with an acute medical illness?

6. Which of the following agents is approved by the Food and Drug Administration for extended outpatient venous thromboembolism prophylaxis in adult patients with acute medical illness?

7. Observational and clinical trials indicate that the highest frequency of VTE events in acutely ill medical patients occurs during which of the following time periods?

8. Which of the following is the correct interpretation of the clinical trial data evaluating short-term versus extended-duration venous thromboembolism prophylaxis in hospitalized patients?

9. The dose of betrixaban approved by the Food and Drug Administration for a patient hospitalized with acute heart failure, creatinine clearance of 40 mL/min, and a history of heart failure with reduced ejection fraction who is receiving amiodarone for treatment of ventricular tachycardia is

10. The 2012 practice guidelines of the American College of Chest Physicians recommend which of the following options for venous thromboembolism prophylaxis in acutely ill medical patients?

« Return to Activity

Customers who Purchased
this Activity also Purchased